PDE8A RNA Editing Biomarker for Mood Disorder Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an effective, validated biological test for predicting the risk of suicidal behavior or depressive disorders, as existing tests are not approved by regulatory agencies and have limited accuracy in identifying individuals at risk.
Innovation Solution
An in vitro method that analyzes PDE8A mRNA expression and RNA editing levels in body fluids, using ADAR enzymes, to determine the relative proportion of RNA editing sites and isoforms associated with psychiatric disorders, employing statistical models and machine learning algorithms for accurate risk prediction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If clinical evaluation methods are used to predict suicidal behavior risk, then the assessment can be performed without specialized equipment, but the prediction accuracy is insufficient and cannot reliably identify individuals at risk
Solution Approach 1:
The patent replaces traditional clinical evaluation methods (mechanical/physical assessment) with a molecular biology-based diagnostic system that measures RNA editing levels of PDE8A in blood samples. This substitution enables objective, quantifiable measurement of suicidal behavior risk through biochemical markers rather than subjective clinical judgment, thereby improving prediction accuracy while maintaining relative simplicity through standardized laboratory procedures
Solution Approach 2:
The patent introduces RNA editing levels of PDE8A as an intermediary biomarker that mediates between genetic predisposition and suicidal behavior manifestation. This intermediary provides a measurable link between molecular changes and clinical outcomes, enabling indirect but accurate prediction of suicidal risk without requiring direct observation of behavioral symptoms
2Reliability
If pharmacological treatments are applied to psychiatric diseases, then symptom management can be provided, but the rate of attempted and completed suicides is not significantly decreased
Solution Approach 1:
The patent enables preliminary identification of individuals at high risk for suicidal behavior through RNA editing level assessment before psychiatric crises occur. This preliminary detection allows for preventive interventions to be implemented earlier in the disease trajectory, potentially preventing suicide attempts before they happen rather than merely managing symptoms after psychiatric illness develops
Solution Approach 2:
The patent establishes a feedback mechanism by measuring RNA editing levels of PDE8A that reflect the functional state of neuronal circuits involved in suicidal behavior. This molecular feedback provides objective information about treatment response and risk status, allowing for dynamic adjustment of preventive strategies based on actual biological changes rather than relying solely on clinical symptom assessment
3Measurement precision
If RNA editing analysis of PDE8A is performed in brain tissues, then the most direct measurement of psychiatric disorder risk can be obtained, but the sampling procedure becomes highly invasive and impractical
Solution Approach 1:
The patent exploits the copying principle by utilizing blood-based RNA editing levels of PDE8A that mirror or reflect the editing levels in brain tissues. Since PDE8A is expressed in both brain and blood tissues and edited by ADARs in humans, the blood sample serves as a accessible copy or surrogate that provides the same diagnostic information as direct brain tissue analysis would, but without the invasiveness of neurological procedures
Solution Approach 2:
The patent uses blood as an intermediary medium that connects the inaccessible brain tissue to the external diagnostic system. Blood serves as a liquid biopsy that carries molecular information from the central nervous system, enabling indirect measurement of brain RNA editing status through a readily accessible peripheral compartment without requiring direct brain sampling
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a high-accuracy, non-invasive means to identify individuals at risk for psychiatric disorders, including suicidal behavior, by analyzing PDE8A transcripts in blood samples, offering a potential tool for early intervention and prevention strategies.
Implementation Method 1
alteration of A-to-I editing on PDE8A transcripts
Data Source
AI summary
The present invention is drawn to a method for in vitro predicting the risk for a patient to present a pathology or to identify whether a patient is at risk to develop a pathology, such as psychiatric disorder, associated to an alteration of A-to-I editing on PDE8A transcripts, from body fluids such as a blood, urine or saliva sample of said patient. The present invention also relates to kits for the implementation of the method.